Clinical Study
Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
Table 1
Clinical characteristic of patients.
| | Characteristics | |
| | | Median (range) | | Age (years) | 49.6 (30–70) | | Tumor size (cm) | 3 (1–9) | | Number of positive nodes | 2 (1–37) | | Side of involved | No. (%) | | Right | 28 (46.7%) | | Left | 32 (53.3%) | | Histology | | | Ductal | 53 (89.8) | | Lobular | 3 (5) | | Others | 4 (5.2) | | Hormone receptors | | | ER | | | Positive | 43 (75.4) | | Negative | 14 (24.6) | | PR | | | Positive | 36 (63.2) | | Negative | 21 (36.8) | | HER-2 | | | Positive | 32 (58.2) | | Negative | 23 (41.8) | | Hormone therapy | | | Positive | 47 (78.3) | | Negative | 13 (21.7) | | Regimen of hormone therapy | | | Tamoxifen | 28 (59.6) | | Others | 19 (40.4) |
|
|
ER: estrogen receptors; PR: progesterone receptors.
|
